Celadon Pharmaceuticals PLC Result of AGM (4485E)

TIDMCEL

RNS Number : 4485E

Celadon Pharmaceuticals PLC

29 June 2023

Celadon Pharmaceuticals Plc

("Celadon" or the "Company")

Result of Annual General Meeting

London, UK, 29 June 2023 : Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the research, cultivation, manufacturing and sale of breakthrough cannabis-based medicines, announces that at its Annual General Meeting held today, all resolutions were duly passed.

Full details of the poll results will shortly be set out on the Company's website .

Enquiries:

 
 
 Celadon Pharmaceuticals Plc 
 James Short                                    Via Powerscourt 
  Arthur Wakeley 
  Jonathan Turner 
 
 Canaccord Genuity Limited (Nominated 
  Adviser and Broker) 
 Bobbie Hilliam / Andrew Potts / Patrick 
  Dolaghan                                      +44 (0)20 7523 8000 
 
 Powerscourt Group 
 Sarah MacLeod / Nick Johnson / Sam Austrums 
  / 
  Ibrahim Khalil                                +44 (0)20 7250 1446

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its GMP pharmaceutical cannabis product. The Company's subsidiary, LVL, owns a MHRA conditionally-approved clinical trial using cannabis based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics which is developing a licenced cannabinoid medicine to treat children with Autism Spectrum Disorder.

For further information please visit our website www.celadonpharma.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGNKCBDABKDPAB

(END) Dow Jones Newswires

June 29, 2023 12:30 ET (16:30 GMT)

Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Apr 2024 to May 2024